Prostaglandin E2 Receptor 4 (EP4R) Inhibitors-Pipeline Analytics 2022

EP4R Inhibitors report covers the EP4R Inhibitors market opportunity providing Key Competitive Analysis, 16+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partners as well as Clinical Partner. The report covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area, and indication by phases. EP4R inhibitor's reports add value in terms of describing clinical stage products concerning their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

SAMPLE VIEW

Given the multiple tumor-promoting roles of EP4 expression on tumor cells and host immune cells and endothelial cells, revealed that the combination of EP4 antagonists and other immunomodulating drugs should work synergistically, especially in TNBCs displaying a diverse microenvironment. This strongly suggests the potential benefit of EP4 antagonists in combination with other immunomodulating agents in cancer therapy.

In this report, Mellalta Meets provides an in-depth analysis of EP4R inhibitors covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy areas, investments, and acquisition trends. Currently, there are more than 12 candidate EP4R inhibitor products currently under evaluation in clinical and preclinical studies. The major key players operating in the market are Rottapharm Biotech, Haihe Biopharma/3D Medicine, Bristol-Myers Squibb/Ono Pharmaceuticals, Ikena Oncology, and many more which have robust clinical pipelines of EP4R inhibitor candidates.

As per analysis, the EP4 receptor is currently emerging as the most versatile and promising among PGE2 receptors with the development pipeline full of Molecules like small molecules and combination therapies.

Key Highlights of EP4R Inhibitors Report:

• There are ~5 products in the Phase 1 stage of development, representing 41.67% of the total share of the developing EP4R inhibitors landscape. The remaining 58.33% has been contributed by pre-clinical (25%); Phases 2 and 1/2 (16.67%).

• The pipeline of EP4R Inhibitors is dominated by biotech companies headquartered in China with Chinese companies holding the top 6 positions. They represent ~37.50% of all the pipeline EP4R inhibitors in clinical stages.

• EP4R Inhibitors pipeline landscape includes 47% of Monotherapy trials and 53% of Combination Trials

• The pipeline of EP4R inhibitors is dominated by Phase 1 (5); Pre-clinical (3); Phase 2 (2) assets and Phase 1/2 (2) assets.

• To be continued...

Report Coverage:

• Indication Prioritisation: EP4R Inhibitors market potential based on Indications

• Business Transactions & Strategies: Key collaborations and deal values

• EP4R Inhibitors Pipeline Development: Product Profiles, Clinical Trials & Results

• EP4R Inhibitors Acquisition Targets

• EP4R Inhibitors Competitive Intelligence

• Recent & Upcoming events